Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0596263 (carcinogenesis)
 64,820 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Methapyrilene ([14C]MPH) was found to bind to calf thymus DNA only after activation by both rat liver microsomes and NADPH. The cytochrome P-450 inhibitors 2,4-dichloro-6-phenylphenoxyethylamine, 2-diethylaminoethyl-2,2-diphenylvalerate and metyrapone inhibited binding, but methimazole, a flavin-dependent monooxygenase inhibitor, had no effect. However, 1,2-epoxy-3,3,3-trichloropropane, an epoxide hydrolase inhibitor, decreased binding by 30%. Pre-treatment of rats with isosafrole, pregnenolone-16 alpha-carbonitrile or phenobarbital had little or no effect on binding while 3-methylcholanthrene pretreatment decreased binding by 37%. Incubations in the presence of either N-acetylcysteine, glutathione, catalase or glutathione-peroxidase decreased binding to DNA while superoxide dismutase had no effect. These data suggest that MPH is metabolically activated to a species which binds to DNA and that this activation may be mediated by cytochrome P-450 isozymes.
Carcinogenesis 1987 Oct
PMID:Cytochrome P-450 dependent binding of methapyrilene to DNA in vitro. 311 19

Male ACI/N rats were treated with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in the drinking water, and in conjunction with histological examination, the changes of the expressed cytochrome P-450 components in the urothelium and other tissues (liver, kidney, esophagus, intestines) were examined by means of immunohistochemistry. Frozen tissue sections were prepared and immunostained with anti-rat cytochrome P-450 monoclonal antibodies and an avidin-biotin-peroxidase complex. Monoclonal antibodies used were APH-3 and APH-8 raised against a high-spin form of cytochrome P-448, APL-1 and APL-2 against a low-spin form of cytochrome P-448, and APF-3 against cytochrome P-450. BBN-induced qualitative and quantitative changes of cytochrome P-450 components recognized by these monoclonal antibodies were not observed in tissues other than the bladder. Untreated rat bladder epithelium was not stained with any of these 5 monoclonal antibodies. The treatment with BBN for more than 3 weeks, however, resulted in the expression of cytochrome P-450 component(s) recognized by APH-8 antibody. This cytochrome P-450 component increased with the advance of carcinogenic changes in the urothelium. The component reactive with AHP-8 was also detected in the cancer tissues of transplantation lines of rat bladder cancers. In contrast, the cytochrome P-450 components recognized by APL-1, APL-2 or APF-3 were undetectable or present at low levels throughout the BBN carcinogenesis. These results suggest that a certain cytochrome P-450 component(s), probably a high-spin form of cytochrome P-448, is selectively induced in urothelium in association with neoplastic bladder lesion.
 ...
PMID:Altered expression of immunohistochemically detected cytochrome P-450 component(s) in nitrosamine-induced rat urinary bladder lesion. 311 31

Fried ground beef contains substances that inhibit mutagenesis in bacteria and the initiation of epidermal carcinogenesis in mice by 7,12-dimethylbenz [a]anthracene (DMBA). The inhibitors apparently act at least in part via inhibition of cytochrome P-450 activity. A highly purified fraction that inhibited cytochrome P-450 activity in vitro was isolated by HPLC and characterized by GC-MS, and by UV and proton NMR spectroscopy. The fraction contained four isomeric derivatives of linoleic acid each containing a conjugated double-bond system (designated CLA). Synthetically prepared CLA (containing all four isomers) was tested for anti-initiation activity in the two-stage mouse epidermal carcinogenesis system. Seven days, 3 days and 5 min prior to DMBA application, CLA was applied at doses of 20, 20 and 10 mg respectively. Control mice were treated similarly with linoleic acid or solvent (acetone). One week after initiation, and twice weekly thereafter, all mice were treated with 12-O-tetradecanoylphorbol-13-acetate to effect tumor promotion. There was no difference in tumor incidence or yield between linoleic acid-treated mice and solvent-treated control mice. By contrast, the CLA-treated mice developed only about half as many papillomas and exhibited a lower tumor incidence compared with the control mice.
Carcinogenesis 1987 Dec
PMID:Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid. 311 46

The enzymatic activation of a promutagenic pyrolysate, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), was studied using the Ames mutagenesis test system. The enzyme catalyzing the mutagenic activation of MeIQx is mainly localized in the microsomal fraction. A large number of revertants was observed in the presence of hepatic microsomes obtained from 3-methylcholanthrene (3-MC)- or polychlorinated biphenyl (PCB)-treated rats but only a minimal number with the hepatic microsomes from untreated or phenobarbital (PB)-treated rats. In addition, the microsomal activation was reduced efficiently by known inhibitors of cytochrome P-450-mediated reactions such as 7,8-benzoflavone, ellipticine and flavone. Among five forms of purified rat cytochrome P-450, the highest sp. act. (no. of revertants induced/nmol cytochrome P-450) for the activation of MeIQx was observed with a high-spin form of cytochrome P-450, P-448-H, followed by the low-spin form, P-448-L, and to a lesser extent by PB-inducible forms, P-450b and P-450e. P-450-male, which is a main constitutive form of cytochrome P-450 in male rat livers, showed considerable catalysis for the mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and MeIQx. These results indicate that the metabolic activation of MeIQx is catalyzed mainly by two forms of cytochrome P-450, P-448-H and P-488-L, in the livers of PCB- or 3-MC-treated rats, but also that P-450-male may play an important role in the activation in livers of intact male rats.
Carcinogenesis 1988 Jan
PMID:Metabolic activation of a protein pyrolysate promutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline by rat liver microsomes and purified cytochrome P-450. 312 Dec 5

Certain chemical inducers of rat liver microsomal cytochrome P-450d are tightly bound to the cytochrome. We investigated the ability of two inducers of cytochrome P-450d, Aroclor 1254 and isosafrole, to inhibit the microsomal activation of 2-aminofluorene to a mutagen as measured in Salmonella typhimurium. Butanol treatment of microsomes from isosafrole-treated rats removed an inhibitory metabolite of isosafrole and increased 2-aminofluorene mutagenesis by approximately 2-fold over controls. Butanol treatment of microsomes from Aroclor 1254-treated rats failed to either remove any of the Aroclor 1254 associated with microsomal cytochrome P-450 or affect 2-aminofluorene-induced mutagenesis. However, addition of Aroclor 1254 to butanol-treated microsomes from isosafrole-treated rats almost completely inhibited 2-aminofluorene mutagenesis. Aroclor 1254 completely inhibited the cytochrome P-450d-dependent estradiol 2-hydroxylase activity of butanol-treated microsomes from isosafrole-treated rats. Thus, we suspect that certain congeners from Aroclor 1254, a widely used mixture for induction of cytochrome P-450 activities, could inhibit cytochrome P-450d and partially mask its ability to metabolize some chemicals to mutagens.
Carcinogenesis 1988 Feb
PMID:Inhibition of 2-aminofluorene mutagenesis in bacteria by inducers of cytochrome P-450d. 312 85

Studies were carried out, using antibodies to specific cytochrome P-450 isozymes, to identify the isozymes involved in the NADPH-dependent activation of 3,3'-dichlorobenzidine (DCB) by rat hepatic microsomes to mutagens in the Ames test. DCB activation was not affected by a monoclonal antibody specific for P-450c or by a monoclonal antibody specific for P-450b, but was inhibited 69% by a polyclonal antibody made against P-450d. DCB activation was also inhibited 46% by antibody specific for NADPH-cytochrome P-450 reductase. Further, addition of methimazole, a high affinity substrate for the flavin-containing monooxygenase, reduced the residual mutagenicity in the systems containing antibody to P-450d and cytochrome P-450 reductase to 9% and 19%, respectively, of the appropriate control values. It is concluded that P-450d contributes to a majority of the P-450-dependent activation of DCB in hepatic microsomes. The results also suggest that the flavin-containing monooxygenase may contribute to the microsomal activation of DCB.
Carcinogenesis 1988 May
PMID:Activation of 3,3'-dichlorobenzidine in rat liver microsomes to mutagens: involvement of cytochrome P-450d. 313 Feb 2

The rates of formation of diols of dimethylbenz[a]anthracene (DMBA-3,4-diol, DMBA-5,6-diol and DMBA-8,9-diol) have been determined in hepatic microsomes prepared from untreated rats or from animals treated with phenobarbital (PB) or Sudan III. PB treatment enhanced the formation of the proximate carcinogen, DMBA-3,4-diol, and of the 5,6-diol while treatment with Sudan III suppressed the formation of DMBA-3,4-diol but greatly increased the rates of formation of the other two diols. Metyrapone, a reagent which is specific for members of the major PB-induced cytochrome P-450 subfamily (P-450-PB3), did not alter the rate of formation of the diols other than in microsomes prepared from PB-treated animals in which formation of the 5,6-diol was inhibited. Incubation of DMBA with microsomes resulted in the formation of covalent, DMBA-microsome adducts. Treatment of the animals with PB and Sudan III increased the rate of formation of DMBA-microsome adducts to a similar extent (approximately 5-fold). The formation of adducts could be inhibited by metyrapone in microsomes from untreated and PB-treated animals but the reagent had no effect on adduct formation in microsomes from Sudan III-treated animals. These observations may indicate that adduct formation in microsomes from Sudan-treated animals involves primary epoxide metabolites while in microsomes from PB-treated animals secondary metabolites are involved and these may be formed by a P-450-PB3 isoenzyme. Specific P-450 isoenzymes involved in the regioselective formation of DMBA-diols have been identified by the use of antibodies directed against specific isoenzymes. An antibody to P-450-MC1b inhibited the formation of DMBA-5,6-diol and 8,9-diol in microsomes from Sudan III-treated animals. Western blot analysis demonstrated that P-450-MC1b was induced in microsomes of animals treated with Sudan III but was not present in the other two microsomal preparations. In accord with the observations with metyrapone, anti-P-450-PB3 inhibited formation of DMBA-5,6-diol in microsomes from PB-treated animals but was without effect on the formation of other diols. Anti-P450-PB1 inhibited the formation of DMBA-3,4-diol in microsomes from PB-treated animals. Western blot analysis of microsomes from animals treated with several xenobiotics indicated a qualitative correlation between the content of P-450-PB1 and the rate at which DMBA-3,4-diol was formed.
Carcinogenesis 1988 Aug
PMID:Role of specific cytochrome P-450 isoenzymes in the regio-selective metabolism of 7,12-dimethylbenz[a]anthracene in microsomes from rats treated with phenobarbital or Sudan III. 313 57

Rainbow trout (Salmo gairdneri) and coho salmon (oncorhynchus kisutch) were exposed to aflatoxin B1 (AFB1) either by passive embryo uptake or by dietary treatment after hatching and feeding onset. Trout exposed as embryos to an aqueous solution of 0.5 p.p.m. AFB1 for 15 min showed a 62% tumor incidence 12 months later, whereas coho salmon exposed to a similar solution for 30 min showed only a 9% incidence. The difference between salmon and trout response was even greater by dietary AFB1 treatment. Trout exposed for 4 weeks to 20 p.p.b. dietary AFB1 had a 62% tumor response 12 months later, whereas salmon exposed to 40 p.p.b. dietary AFB1 for 4 weeks failed to develop tumors. A 5% tumor incidence was observed in salmon 12 months after 3 weeks exposure to 5000 p.p.b. dietary AFB1, a lethal dose for trout. In addition to a lower tumor incidence when compared to trout, the neoplastic response of salmon to AFB1 is to produce benign hepatic adenomas in contrast to the malignant hepatocellular carcinomas seen in trout. AFB1 metabolism, DNA adduct formation, adduct persistence in vivo and in vitro and cytochrome P-450 isozyme composition were compared in livers of trout and salmon to understand the role of metabolism and initiation in this species difference. AFB1-DNA binding was 7-56 times greater in trout than salmon liver at various times after AFB1 injection, 20 times greater in embryos or in freshly isolated trout hepatocyte preparations after a 1 h incubation with aflatoxin B1, and 18 times greater in trout liver after a three week dietary (80 p.p.b.) exposure. The major AFB1-DNA adduct was 8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 in both species. Persistence of AFB1-DNA adducts in vivo in liver was high compared to mammalian systems, implying that active enzymatic removal of bulky DNA adducts is low in both species and probably not a factor in their differential response to aflatoxin. Species differences in other phase I and phase II metabolism pathways and in AFB1 elimination were, overall, much less striking than those previously observed for trout fed inhibitors of aflatoxin carcinogenesis. Rates of bile elimination of AFB1 detoxication products, and total excretion of aflatoxins into water after AFB1 exposure, were not significantly different between trout and salmon. Since detoxication differences were not observed, the species difference in AFB1-DNA binding appears to reflect less efficient cytochrome P-450 metabolism of aflatoxin to the reactive 8,9-epoxide in salmon, compared to trout.(ABSTRACT TRUNCATED AT 400 WORDS)
Carcinogenesis 1988 Nov
PMID:Aflatoxin B1 carcinogenesis and its relation to DNA adduct formation and adduct persistence in sensitive and resistant salmonid fish. 314 Oct 73

We measured the ability of neonatal to adult MRC-Wistar rat and Syrian hamster tissues to convert the esophageal carcinogen methyl-n-amylnitrosamine (MNAN) into the stable metabolites 2- to 5-hydroxy-MNAN and 3- and 4-oxo-MNAN. Slices or pieces of freshly removed tissues were incubated for 3 h with 23 microM MNAN and dichloromethane extracts were analyzed by gas chromatography-thermal energy analysis. The sum of the metabolites was expressed as percent metabolism of MNAN/100 mg tissue ("percent metabolism"). Tissues of animals from 1 day before birth to 56-70 days of age were examined. Metabolites in rat esophagus reached 12.6% at 6 days of age, three times the adult level, and that in hamster esophagus reached 13.1% at birth, 22 times the adult level. Forestomach metabolism was 1.9% in 3-day rats and 5.7% in 3-day hamsters, though the adult levels were less than 0.5%. Metabolism in rat, but not hamster, liver showed a peak at 9 days that was 3.6 times the adult level. Hamster, but not rat, skin showed about 1% metabolism. Total metabolism by glandular stomach, lung, and trachea of both species also showed changes with age. Ratios between 2-, 3-, 4-, and 5-hydroxy-MNAN were of three types: considerable 2-, 3-, and 4-hydroxy-MNAN, typical of esophagus; mainly 4-hydroxy-MNAN, typical of liver; and mainly 5- with some 4-hydroxy-MNAN, typical of rat lung. Incubation of adult rat liver and esophagus with varied MNAN concentrations showed apparent Km values of 150 (esophagus) and 300 (liver) microM. Metabolite yields after young and adult rat esophagus and liver were incubated with 23 microM MNAN for 1, 2, or 3 h indicated that differing in vitro stability of enzyme activities did not explain the age differences. The 2.9- to 3.6-fold differences in total metabolite yield between young and adult rat esophagus and liver, observed when these tissues were incubated with 23 microM MNAN, was in contrast to the 1.3- to 1.6-fold difference when these tissues were incubated with 300 or 600 microM MNAN, suggesting that much of the observed age difference was specific to low MNAN concentrations. MNAN hydroxylation could be used to indicate tissue susceptibility to MNAN carcinogenesis and the presence of enzymes (probably cytochrome P-450 isozymes) that catalyze each of the three types of MNAN metabolism.
 ...
PMID:Hydroxy metabolites of methyl-n-amylnitrosamine produced by esophagus, stomach, liver, and other tissues of the neonatal to adult rat and hamster. 316 24

The aim of this study was to optimize the pH in the liver microsomal assay (LMA) in processing short-term mutagenicity tests. pH optimization would increase the sensitivity (i.e. decrease the presence of false negatives) and increase the specificity (decrease false positives). Such optimization is a function of the relative activities and stabilities of the liver microsomal cytochrome P-450- and FAD-containing monooxygenase-dependent biotransformation enzymes present in the incubation mixtures used. The enzyme activities ethoxyresorufin O-deethylase, dinemorphan N-demethylase, aminopyrine N-demethylase, p-nitroanisole O-demethylase and thiobenzamide S-oxidase (as phase-I markers), were examined in terms of their exact incubation conditions for the LMA during a period of pre-incubation (1 h) over the pH range 6-9. As a comparison, the behaviours of glutathione S-transferase and epoxide hydrase activities (as phase-II markers) were also studied. Lipid peroxidation was also determined. Experiments were carried out on S9 fractions derived from Na-phenobarbital and beta-naphthoflavone induced mouse liver. The maximal value of the mean specific activity (Asp) was found at pH 7.8 for the phase-I drug metabolizing enzymes considered (30-45% increase). On the contrary, a lower increase of Asp for epoxide hydrase and glutathione S-transferase (approximately 14%), was observed between pH 7.4 and 7.8. Lipid peroxidation was not changed appreciably by varying pH. In vitro DNA binding of the well-known pre-mutagenic agent [14C]dimethylnitrosamine ([14C]DMNA), mediated by mouse hepatic microsomal enzymes, showed a significant increase of specific activity at pH 7.8 (2.8-fold) compared to the usual pH (7.4) employed. Additional support for the above results has come from mutagenesis experiments using DMNA on the diploid D7 strain of Saccharomyces cerevisiae as a biological test system. In fact, a significant enhancement of mitotic gene conversion (1.7-fold), mitotic cross-over (2.6-fold) and reverse point mutation (2.3-fold) frequencies were observed at pH 7.8 compared to pH 7.4. These data indicate that pH 7.8 provides a more favourable condition for in vitro mutagenesis tests resulting in greater rates of biotransformation (as measured by an increased Asp phase-I/Asp phase-II ratio), DNA binding and genotoxic response.
Carcinogenesis 1988 Dec
PMID:Improvement of short-term tests for mutagenicity: on the optimal pH for the liver microsomal assay. 319 71


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>